Stephen C Pflugfelder1, Mina Massaro-Giordano2, Victor L Perez3, Pedram Hamrah4, Sophie X Deng5, Ladan Espandar6, C Stephen Foster7, John Affeldt8, John A Seedor9, Natalie A Afshari10, Wendy Chao11, Marcello Allegretti11, Flavio Mantelli11, Reza Dana12. 1. Department of Ophthalmology, Baylor College of Medicine, Houston, Texas. 2. Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Bascom Palmer Eye Institute, University of Miami, Plantation, Florida. 4. New England Eye Center, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts. 5. Stein Eye Institute, University of California, Los Angeles, Los Angeles, California. 6. Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania; Sightline Ophthalmic Associates, Pittsburgh, Pennsylvania. 7. Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts. 8. Loma Linda University Eye Institute, Loma Linda, California. 9. New York Eye and Ear Infirmary of Mt. Sinai School of Medicine, New York, New York. 10. Shiley Eye Institute, University of California, San Diego, La Jolla, California. 11. Dompé Farmaceutici SpA, Milan, Italy. 12. Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts. Electronic address: reza_dana@meei.harvard.edu.
Abstract
PURPOSE: To evaluate the efficacy and safety of topical cenegermin (recombinant human nerve growth factor) in patients with neurotrophic keratopathy. DESIGN: Multicenter, randomized, double-masked, vehicle-controlled trial. PARTICIPANTS: Patients with neurotrophic persistent epithelial defect with or without stromal thinning. METHODS: The NGF0214 trial, conducted among 11 sites in the United States, randomized 48 patients 1:1 to cenegermin 20 μg/ml or vehicle eye drops, 6 drops daily for 8 weeks of masked treatment. Follow-up was 24 weeks. Safety was assessed in all patients who received study drug. Efficacy was assessed by intention to treat. MAIN OUTCOME MEASURES: The primary end point was healing of the neurotrophic lesion (persistent epithelial defect or corneal ulcer) after 8 weeks of masked treatment. Masked central readers measured neurotrophic lesions in randomized clinical pictures, then assessed healing status conventionally (<0.5 mm of fluorescein staining in the greatest dimension of the lesion area) and conservatively (0-mm lesion staining and no other residual staining). Secondary variables included corneal healing at 4 weeks of masked treatment (key secondary end point), overall changes in lesion size, rates of disease progression, and changes in visual acuity and corneal sensitivity from baseline to week 8. RESULTS: Conventional assessment of corneal healing showed statistically significant differences at week 8: compared to 7 of 24 vehicle-treated patients (29.2%), 16 of 23 cenegermin-treated patients (69.6%) achieved less than 0.5 mm of lesion staining (+40.4%; 95% confidence interval [CI], 14.2%-66.6%; P = 0.006). Conservative assessment of corneal healing also reached statistical significance at week 8: compared to 4 of 24 vehicle-treated patients (16.7%), 15 of 23 cenegermin-treated patients (65.2%) achieved 0 mm of lesion staining and no other residual staining (+48.6%; 95% CI, 24.0%-73.1%; P < 0.001). Moreover, the conservative measure of corneal healing showed statistical significance at week 4 (key secondary end point). Compared to vehicle, cenegermin-treated patients showed statistically significant reductions in lesion size and disease progression rates during masked treatment. Cenegermin was well tolerated; adverse effects were mostly local, mild, and transient. CONCLUSIONS:Cenegermin treatment showed higher rates of corneal healing than vehicle in neurotrophic keratopathy associated with nonhealing corneal defects.
RCT Entities:
PURPOSE: To evaluate the efficacy and safety of topical cenegermin (recombinant humannerve growth factor) in patients with neurotrophic keratopathy. DESIGN: Multicenter, randomized, double-masked, vehicle-controlled trial. PARTICIPANTS: Patients with neurotrophic persistent epithelial defect with or without stromal thinning. METHODS: The NGF0214 trial, conducted among 11 sites in the United States, randomized 48 patients 1:1 to cenegermin 20 μg/ml or vehicle eye drops, 6 drops daily for 8 weeks of masked treatment. Follow-up was 24 weeks. Safety was assessed in all patients who received study drug. Efficacy was assessed by intention to treat. MAIN OUTCOME MEASURES: The primary end point was healing of the neurotrophic lesion (persistent epithelial defect or corneal ulcer) after 8 weeks of masked treatment. Masked central readers measured neurotrophic lesions in randomized clinical pictures, then assessed healing status conventionally (<0.5 mm of fluorescein staining in the greatest dimension of the lesion area) and conservatively (0-mm lesion staining and no other residual staining). Secondary variables included corneal healing at 4 weeks of masked treatment (key secondary end point), overall changes in lesion size, rates of disease progression, and changes in visual acuity and corneal sensitivity from baseline to week 8. RESULTS: Conventional assessment of corneal healing showed statistically significant differences at week 8: compared to 7 of 24 vehicle-treated patients (29.2%), 16 of 23 cenegermin-treated patients (69.6%) achieved less than 0.5 mm of lesion staining (+40.4%; 95% confidence interval [CI], 14.2%-66.6%; P = 0.006). Conservative assessment of corneal healing also reached statistical significance at week 8: compared to 4 of 24 vehicle-treated patients (16.7%), 15 of 23 cenegermin-treated patients (65.2%) achieved 0 mm of lesion staining and no other residual staining (+48.6%; 95% CI, 24.0%-73.1%; P < 0.001). Moreover, the conservative measure of corneal healing showed statistical significance at week 4 (key secondary end point). Compared to vehicle, cenegermin-treated patients showed statistically significant reductions in lesion size and disease progression rates during masked treatment. Cenegermin was well tolerated; adverse effects were mostly local, mild, and transient. CONCLUSIONS: Cenegermin treatment showed higher rates of corneal healing than vehicle in neurotrophic keratopathy associated with nonhealing corneal defects.
Authors: Fu-Shin X Yu; Patrick S Y Lee; Lingling Yang; Nan Gao; Yangyang Zhang; Alexander V Ljubimov; Ellen Yang; Qingjun Zhou; Lixin Xie Journal: Prog Retin Eye Res Date: 2022-01-04 Impact factor: 19.704
Authors: Gala Beykin; Laurel Stell; Muhammad Sohail Halim; Mariana Nuñez; Lilia Popova; Bac T Nguyen; Sylvia L Groth; Amy Dennis; Zhongqiu Li; Melissa Atkins; Tom Khavari; Sophia Y Wang; Robert Chang; Ann C Fisher; Yasir J Sepah; Jeffrey L Goldberg Journal: Am J Ophthalmol Date: 2021-11-13 Impact factor: 5.488
Authors: Gemma Eftimiadi; Marzia Soligo; Luigi Manni; Daniela Di Giuda; Maria Lucia Calcagni; Antonio Chiaretti Journal: Neural Regen Res Date: 2021-09 Impact factor: 5.135